Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D006321:Heart / Q000187:drug effects; D006801:Humans; D015255:Idarubicin; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged
D000970:Antineoplastic Agents; D015255:Idarubicin; D003630:Daunorubicin